From today's Times:

Tiddler to watch

"ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may attract the attention of Rituxan's developers, Genentech and Biogen Idec."

OK, I know we're all heartily sick of the promising small pharmacos, but I thought I'd bring this one to your attention because the demise of one much-hyped drug can indeed have a positive knock-on effect elsewhere. Furthermore, there doesn't seem to be much medication out there for Lupus.

This company is run by experienced people who have previously worked for some of the majors like GSK, Bristol-Myers Squibb, etc, and in investment banking. Their research results have been positive so far.

I made a good profit on these last year and the sp seems to have turned up again recently. Bought back again this morning. (NB: too small to trade in CFDs)

Gap closed intra-day.

All looking good so far imvho. GLA

Lupuzor™ demonstrated a superior response rate over placebo* (52.5% vs 44.6% "responders"**) in the primary analysis on the Full Analysis Set of all 202 patients (including withdrawals who are considered non-responders). However, due to a high response rate in the placebo group, this superior response did not allow statistical significance to be reached (p = 0.2631) and the trial's primary end point was not met.

===============

OUCH!
serves me right but fortunately not too many
is there now anything left in this company top sell?
if they're lucky, they may be taken out by a bigger fish